NOV 19, 2019 5:22 AM PST

When the numbers don't match: inaccuracy in late state breast cancer survival estimates

According to the World Health Organization, about 2.1 million women are diagnosed with breast cancer annually. It is the cancer that most affects women and to some, especially those patients who receive a late-stage diagnosis of metastatic breast cancer, understanding their chances of survival is key to planning for the future. However, new research suggests that late-stage survival rate estimates are often inaccurate – begging the question, “Are we preparing women for a worst-case scenario that’s likely to not even happen?”

The research was presented by Dr. Belinda Kiely at the fifth International Consensus Conference for Advanced Breast Cancer in Lisbon, Portugal. Dr. Kiely is a cancer specialist at the University of Sydney in Australia studying the relevance and helpfulness of cancer survival estimates for people with late-stage breast cancer. In presenting her work, she explained:

"Every week in my clinic, I meet women of all ages with advanced breast cancer, and they frequently ask: 'How long have I got?' They have very practical concerns and questions that they want help with; for example, they might want to know whether they should cancel a planned holiday, whether they will be able to attend their daughter's wedding, or whether they should stop working or sell their house."

Dr. Kiely is intent on developing a more helpful way of delivering survival rate estimates to patients; she aims to move from the standard technique of presenting patients with a single number estimate (which are only accurate 20-30% of the time, according to her research) to a three-scenario method. In this three-scenario method, doctors have to do some math. After estimating the expected survival time for a patient, physicians can determine a worst-case estimate (by dividing the original number by four) and a best-case estimate (by multiplying by three). Physicians will then present all of these numbers to their patients, noting that typical survival time usually falls between half of the initial estimated survival time and double it.

New research suggests a three-scenario method could improve delivering survival rate estimates for women diagnosed with breast cancer. Photo: Pixabay

"[Cancer specialists] may worry about how much a patient wants to know, whether it's possible to give accurate information, and how best to talk about this without destroying hope," elaborates Dr. Kiely. “Providing patients with a single number estimate of the average survival time is rarely accurate and conveys no hope of a possible longer survival time. Instead, we have devised a method that helps doctors calculate the best case, worst case, and typical survival times for individual patients.”

Dr. Kiely and her team came to these conclusions after working with 33 cancer specialists who advised 146 cancer patients about their estimated survival time. Of the 146 patients involved, 77% reported that they found the three-scenario method either equal to or more optimistic and reassuring than they had expected. In other words, this technique allowed them to stay realistic while also maintaining hope.

Sources: Medical News Today

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
JUN 16, 2020
Cancer
Wearable patch for melanoma patients
JUN 16, 2020
Wearable patch for melanoma patients
Research published in the journal ACS Nano describes a wearable patch that can be used to lessen side effects from chemo ...
JUN 23, 2020
Cancer
Why are certain people more vulnerable to carcinogens?
JUN 23, 2020
Why are certain people more vulnerable to carcinogens?
A study from the University of Hawaii Cancer Center entitled, "Tumour predisposition and cancer syndromes as models ...
JUN 29, 2020
Cancer
Mass Spectrometry and How It Can Profile Cancer
JUN 29, 2020
Mass Spectrometry and How It Can Profile Cancer
Treatments for cancer usually revolve around targeting certain immune checkpoints in the cell. Protein cell death protei ...
JUL 08, 2020
Cancer
Tracking Down Biomarkers for Bladder Cancer Using Mass Spectrometry
JUL 08, 2020
Tracking Down Biomarkers for Bladder Cancer Using Mass Spectrometry
Bladder cancer is one of the most common cancers in the world. Non-muscle invasive bladder cancer (NMIBC) is a precursor ...
JUL 14, 2020
Health & Medicine
Sick Children and Cannabis: A Hospital Offers a Lifeline to Parents
JUL 14, 2020
Sick Children and Cannabis: A Hospital Offers a Lifeline to Parents
A new report in the journal Pediatrics gets the conversation going on a much under-reported area: sick children being ad ...
JUL 23, 2020
Clinical & Molecular DX
Prostate Cancer: To Treat or Not to Treat
JUL 23, 2020
Prostate Cancer: To Treat or Not to Treat
After a prostate cancer diagnosis, urologists do not always initiate immediate clinical intervention. In those with Low- ...
Loading Comments...